The estimated Net Worth of Meredith B Fischer is at least $9.76 mil dollars as of 30 August 2017. Meredith Fischer owns over 1,280 units of Mallinckrodt Plc stock worth over $9,761 and over the last 11 years Meredith sold MNK stock worth over $0.
Meredith has made over 6 trades of the Mallinckrodt Plc stock since 2015, according to the Form 4 filled with the SEC. Most recently Meredith bought 1,280 units of MNK stock worth $50,726 on 30 August 2017.
The largest trade Meredith's ever made was buying 2,200 units of Mallinckrodt Plc stock on 27 November 2015 worth over $147,246. On average, Meredith trades about 434 units every 35 days since 2013. As of 30 August 2017 Meredith still owns at least 28,708 units of Mallinckrodt Plc stock.
You can see the complete history of Meredith Fischer stock trades at the bottom of the page.
Meredith's mailing address filed with the SEC is C/O MALLINCKRODT PLC, 675 JAMES S. MCDONNELL BLVD., HAZELWOOD, MO, 63042.
Over the last 11 years, insiders at Mallinckrodt Plc have traded over $29,853,069 worth of Mallinckrodt Plc stock and bought 2,559,592 units worth $174,429,961 . The most active insiders traders include & Co. Inc. Paulson, James E Deerfield Mgmt L.P...., eNancy Lurker. On average, Mallinckrodt Plc executives and independent directors trade stock every 29 days with the average trade being worth of $10,061. The most recent stock trade was executed by Jason Daniel Goodson on 16 March 2023, trading 1,133 units of MNK stock currently worth $9,495.
mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and central nervous system drugs. the company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. the company's specialty brands segment includes branded medicines; its specialty generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the global medical imaging segment includes contrast media and nuclear imaging agents. to learn more about mallinckrodt, visit
Mallinckrodt Plc executives and other stock owners filed with the SEC include: